Topline data from a Phase 3 clinical trial of buntanetap in early-stage Parkinson’s disease patients is expected soon, according to Annovis Bio, the therapy’s developer. Initially planned for the end of January, ongoing analysis to ensure “clean data” that are accurate and reliable was cited as the reason…

Annovis Bio has announced the last patient completed the final visit in its Phase 3 clinical trial testing buntanetap for people with early-stage Parkinson’s disease. Since the study was initiated in August 2022, more than 616 patients were screened, 523 enrolled, and 471 completed the study across…

Enrollment is now complete for a Phase 3 trial of buntanetap, an oral therapy candidate from Annovis Bio that aims to improve cognitive and motor skills in early-stage Parkinson’s disease, the company has announced. Since the first participant was dosed in August 2022, more than 640 patients…

The first patient has been dosed in a clinical trial testing Annovis Bio’s buntanetap as an oral therapy for early-stage Parkinson’s disease, the company announced. The Phase 3 clinical trial (NCT05357989) got started shortly after the U.S. Food and Drug Administration (FDA) gave the company the…

Excessive sweating, known as hyperhidrosis, is fairly common among people with Parkinson’s and can worsen as the disease progresses, a three-year study of patients in early disease stages reported. Researchers also observed that hyperhidrosis was associated with motor symptoms like dyskinesia (uncontrollable movements) and often accompanied non-motor symptoms…

Machine learning — a form of artificial intelligence that allows a computer to adapt, analyze, and infer from patterns in data — can distinguish by voice people with Parkinson’s disease from those without it and track disease stages by continued changes in voice quality, a study reported. Using speech recordings,…

Green Valley Pharmaceuticals will launch a multi-center Phase 2 clinical trial to investigate its seaweed-based oral compound oligomannate in people with early-stage Parkinson’s disease, according to a press release. This follows the acceptance of Green Valley‘s investigational new drug (IND) application by the U.S Food and Drug…

UCB is partnering with Novartis to co-develop and potentially market UCB0599, a small molecule to inhibit misfolding of the alpha-synuclein protein now in a Phase 2 clinical trial enrolling people with Parkinson’s disease. The agreement also includes an option to co-develop UCB7853 — an antibody against alpha-synuclein —…

Assessing vowel percentage, or duration, during a simple reading task is an effective method to detect changes in speech rhythm at early stages of Parkinson’s disease, according to a small study from Italy. Notably, such rhythmic differences between early-stage Parkinson’s patients and healthy individuals were not as pronounced during…

Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.   UCB’s experimental oral therapy UCB0599 was generally well tolerated in people with mild to moderate Parkinson’s disease…